Avidity Biosciences Statistics
Total Valuation
RNA has a market cap or net worth of $5.87 billion. The enterprise value is $4.57 billion.
Important Dates
The last earnings date was Thursday, August 7, 2025, after market close.
Earnings Date | Aug 7, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
RNA has 128.65 million shares outstanding. The number of shares has increased by 48.40% in one year.
Current Share Class | 128.65M |
Shares Outstanding | 128.65M |
Shares Change (YoY) | +48.40% |
Shares Change (QoQ) | +0.30% |
Owned by Insiders (%) | 1.31% |
Owned by Institutions (%) | 92.54% |
Float | 105.53M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | 535.47 |
Forward PS | 1,212.80 |
PB Ratio | 4.69 |
P/TBV Ratio | 4.82 |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | 425.67 |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 9.26, with a Debt / Equity ratio of 0.00.
Current Ratio | 9.26 |
Quick Ratio | 8.82 |
Debt / Equity | 0.00 |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -37.76% and return on invested capital (ROIC) is -26.87%.
Return on Equity (ROE) | -37.76% |
Return on Assets (ROA) | -24.01% |
Return on Invested Capital (ROIC) | -26.87% |
Return on Capital Employed (ROCE) | -42.29% |
Revenue Per Employee | $27,440 |
Profits Per Employee | -$1.17M |
Employee Count | 391 |
Asset Turnover | 0.01 |
Inventory Turnover | n/a |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -4.52% in the last 52 weeks. The beta is 0.95, so RNA's price volatility has been similar to the market average.
Beta (5Y) | 0.95 |
52-Week Price Change | -4.52% |
50-Day Moving Average | 33.59 |
200-Day Moving Average | 33.53 |
Relative Strength Index (RSI) | 69.33 |
Average Volume (20 Days) | 3,623,727 |
Short Selling Information
Short Interest | 16.26M |
Short Previous Month | 16.72M |
Short % of Shares Out | 13.62% |
Short % of Float | n/a |
Short Ratio (days to cover) | 9.18 |
Income Statement
In the last 12 months, RNA had revenue of $10.73 million and -$455.74 million in losses. Loss per share was -$3.57.
Revenue | 10.73M |
Gross Profit | -399.71M |
Operating Income | -521.78M |
Pretax Income | -228.68M |
Net Income | -455.74M |
EBITDA | -518.74M |
EBIT | -521.78M |
Loss Per Share | -$3.57 |
Full Income Statement Balance Sheet
The company has $1.18 billion in cash and $5.14 million in debt, giving a net cash position of $1.18 billion or $9.16 per share.
Cash & Cash Equivalents | 1.18B |
Total Debt | 5.14M |
Net Cash | 1.18B |
Net Cash Per Share | $9.16 |
Equity (Book Value) | 1.19B |
Book Value Per Share | 9.87 |
Working Capital | 1.12B |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -$489.98 million and capital expenditures -$12.72 million, giving a free cash flow of -$502.70 million.
Operating Cash Flow | -489.98M |
Capital Expenditures | -12.72M |
Free Cash Flow | -502.70M |
FCF Per Share | -$3.91 |
Full Cash Flow Statement Margins
Gross Margin | n/a |
Operating Margin | -4,863.29% |
Pretax Margin | -4,247.76% |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
RNA does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -48.40% |
Shareholder Yield | -48.40% |
Earnings Yield | -7.93% |
FCF Yield | -8.75% |
Analyst Forecast
The average price target for RNA is $68.40, which is 50.03% higher than the current price. The consensus rating is "Strong Buy".
Price Target | $68.40 |
Price Target Difference | 50.03% |
Analyst Consensus | Strong Buy |
Analyst Count | 15 |
Revenue Growth Forecast (5Y) | n/a |
EPS Growth Forecast (5Y) | n/a |
Stock Forecasts Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
Lynch Fair Value | n/a |
Lynch Upside | n/a |
Graham Number | n/a |
Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
RNA has an Altman Z-Score of 13.15.
Altman Z-Score | 13.15 |
Piotroski F-Score | n/a |